1. INTRODUCTION {#sec1}
===============

Although the therapeutic applications of glyceryl trinitrate (GTN) have been established for over 165 years, until the 1980s little was known about GTN's physiological mechanism of action \[[@r1], [@r2]\]. Then the pioneering research of Furchgott, Ignarro, Murad and Moncada identified nitric oxide (NO) as the endothelium-derived relaxing factor \[[@r3], [@r4]\]. NO is a multifunctional free radical, with a molecular weight of only 30 Da, which has an unshared electron in its outer shell. As a simple

diatomic free radical, NO is a short-lived molecule with a half-life (t~1/2~) between 0.1 to 5s in aqueous solutions, and *in vivo* its levels are continuously modulated by the nitric oxide synthases (NOS) \[[@r5]\]. Its t~1/2~ in aqueous solutions is approximately nine fold shorter compared to hydrophobic solvents and this is mainly due to the autoxidation reaction which occurs in the presence of oxygen \[[@r6]\]. Due to NO's lipophilicity it can readily diffuse through cell membranes and, under physiological conditions, its diffusion constant is similar to molecular oxygen \[[@r7], [@r8]\].

As a signaling molecule NO regulates key physiological processes, such as gene regulation, vasorelaxation, vascular permeability, bronchodilation, platelet aggregation, angiogenesis, neuronal communication, hormone secretion, inflammation, gastrointestinal mobility and wound healing \[[@r9], [@r10]\]. The over or under-production of NO causes or contributes to several pathophysiological conditions including cancer \[[@r11]\]. Over the past decades there have been extensive efforts to investigate the effects of NO on cancer biology, however, the findings are controversial. Overall NO has been termed a double edged sword, as it has both tumoricidal and tumor promoting effects. The concentration and duration of its presence at a particular site are thought to play a prominent role in cancer biology \[[@r12]\].

Inhaled NO is now recognized as an invaluable tool for decreasing pulmonary inflammation, neonatal pulmonary hypertension, and for heart and lung surgery. Beyond these applications it has limited, if any, other clinical value due to its low water solubility, instability and inconvenient handling of authentic aqueous solutions of NO \[[@r13]-[@r15]\]. Hence, there has been increasing interest in the development of NO releasing compounds to generate NO *in situ*.

For cancer therapy the utility of authentic aqueous solutions of NO, and most currently available NO donor agents (consisting of low molecular weight molecules), is highly limited due to their low half-lives, instability under physiological conditions, rapid systemic clearance, unspecific NO release and NO-independent toxicities. With the emergence of nanotechnology, the application of intelligent biomaterials to the controlled delivery of NO has emerged as a unique strategy for tumor targeting.

Herein we discuss the role of NO in cancer biology, and the therapeutic use of NO releasing functional groups, with a focus on the six main groups: organic nitrates, organic nitrites, metal complexes, sydnonimines, diazeniumdiolates, and S-nitrosothiols. We also review current advances in the design of NO releasing biomaterials and their applications for tumor therapy.

2. THE BIOLOGICAL ACTIONS OF NO {#sec2}
===============================

The biological actions of NO can occur *via* direct or indirect chemical reactions. The best characterized example is of NO directly binding to metal complexes of different proteins to form metal nitrosyl complexes, regulating their biological activity \[[@r16]\]. For example, NO reacts with soluble guanylate cyclase (sGC) at its haem moiety; upon binding the enzyme is activated, enabling the catalytic transformation of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). Downstream of this event kinase-media- ted signal transduction proteins responsive to cGMP are activated, such as protein kinase G (PKG). This has been recognized as the principal pathway by which NO mediates many physiolo- gical processes including: smooth muscle relaxa- tion, neurotransmission, inhibition of platelet aggregation and adhesion \[[@r17]\]. For the classical mechanism suggested for vasodilatory effects of NO, PKG sequestrates calcium (Ca^2+^) into intracellular stores *via* stimulation of the sarco-endoplas- mic reticulum Ca^2+^ ATPase (SERCA), thereby decreasing cytoplasmic Ca^2+^ concentration which in- hibits the cell's contractile apparatus \[[@r18]\] through interactions with myosin Fig. **[1](#F1){ref-type="fig"}**. NO-mediated vasodilation also occurs *via* inhibition of Ca^2+^-dependent K^+^ channels \[[@r19]\]. Inhibition of such channels, which are specifically important in cerebral vasodilatation \[[@r20]\], results in depletion of cellular calcium and therefore relaxes the vascular muscle.

In addition to metal binding, NO may also undergo chemical reactions with a variety of endogenous radical species, producing reactive nitrogen species, which are responsible for additional signaling roles and certain types of NO-mediated  toxicity *in vivo*. For instance, the reaction of NO with O~2~ or the superoxide anion (O~2~^•-^) produces nitrogen dioxide (NO~2~) and peroxynitrite (ONOO^-^) respectively \[[@r21]\]. These reactive species act as potent oxidizing and nitrating agents \[[@r21]\] which can result in changes to DNA, lipid peroxidation, and protein modifications *via* nitration, nitrosative and oxidative reactions Fig. **[2](#F2){ref-type="fig"}** \[[@r22]\].

3. NO IN CANCER BIOLOGY {#sec3}
=======================

The role of NO in tumor therapy is diverse. Depending on both the concentration and duration of NO action within the tumor cells, it can affect cancer initiation, enhance cell progression, tumor blood flow, angiogenesis, metastasis, and apoptosis, cell death and tumor suppression (for reviews see \[[@r9], [@r23], [@r24]\]). The targeted release of NO may also provide opportunities for cancer therapy and enhance the efficacy of chemo- and radiotherapy, provided that the appropriate concentration of NO reaches the tumor \[[@r24]\].

Vannini *et al*. have recently categorized the concentration of NO in tissue as low (50-100 nM), intermediate (100-400 nM) or high (400-1000 nM) \[[@r25]\]. At low and intermediate concentrations, NO normally stimulates cancer cell progression, prevents apoptosis and enhances angiogenesis and metastasis *via* various signaling pathways which are crucial for tumor cell survival, such as the extracellular signal-regulated kinase (ERK), Akt, mammalian target of rapamycin (mTOR), Ras and epidermal growth factor receptor (EGFR) pathways \[[@r23]\]. Higher concentrations of NO are recognized as having an anti-tumor effects by inducing apoptosis and sensitizing tumors to chemo- and radiotherapy \[[@r24]\], however the exact mechanisms responsible for establishing different NO activities are unknown. It appears that there is a gradation of NO effectiveness in activating these different pathways \[[@r26]-[@r28]\] (Fig. **[3](#F3){ref-type="fig"}**. For example, stimulation of MCF-7 breast cancer cells, macrophages, or endothelial cells with activation of PKG, increased ERK-P and Akt-P expression at low nM levels of NO (10-60 nM). Increased hypoxia-induced factor 1 alpha (HIF-1α) expression was then detected at approximately 100 nM NO \[[@r29], [@r30]\], while p53 expression was associated with higher levels of NO that led to apoptosis \[[@r31]\]. In addition, NO is known as a physiological regulator of mitochondrial respiration \[[@r32]\]. At both low and high concentrations it inhibits mitochondrial respiration by different mechanisms \[[@r32]\]. At low concentrations NO inhibits cytochrome c oxidase in competition with oxygen, and this process is fully reversible \[[@r33]\]. Probably by nitrosating or oxidising thiol centers of proteins and reacting with the iron-sulfur centers, at high concentrations NO inhibits the respiratory chain complexes I, II and V, as well as creatine kinase \[[@r32]\]. This results in depolarization of the mitochondrial membrane and induces swelling and calcium release \[[@r34]\].

Due to the complexity of the signaling pathways involved, NO administration may result in different effects on cancer. For example, S-nitroso-N-acetyl-DL-penicillamine (SNAP) inhibited cell proliferation in umbilical vein endothelial cells \[[@r35]\], while in mouse clonal osteogenic cells it stimulated cell proliferation \[[@r36]\]. In addition, the expression of NOS has been investigated in several *in vitro* and *in vivo* cancer studies (for review see \[[@r25]\]). In animal models, depending on the tumor microenvironment and the tumor type, NOS overexpression resulted in tumorigenic or anti-tumor effects \[[@r37]-[@r39]\]. Similarly, it has both pro- and anti-metastatic effects \[[@r40]\]. In metastasis, epithelial cells lose normal cell-cell adhesion and gain mesenchymal markers which promote cell migration and invasion, a process known as  epithelial to mesenchymal transition (EMT) \[[@r41]\]. Emerging evidence has shown that the NF‐κB family of transcription factors are pivotal regulators of both promoting and maintaining an invasive phenotype \[[@r42]\]. Several studies have shown that a high level of NO, delivered *via* NO donors such as diethylenetriamine NONOate (DETA/NO), inhibits the EMT phenotype in metastatic cancer cell lines by dysregulation of NF‐κB \[[@r43], [@r44]\]. However others have reported that NO facilitated the induction of MET and tumor invasion \[[@r45]\].

4. DRUG DELIVERY SYSTEMS AND EFF- ECTS OF NO ON EPR BASED ANTICAN- CER-DRUG DELIVERY {#sec4}
====================================================================================

In cancer therapy, biomacromolecules larger than 40 kDa have been developed as drug carriers to promote tumor targeting. The macromolecules that are traditionally used for drug delivery systems (DDS) include; liposomes, polymeric nanoparticles, micelles, dendrimers and inorganic nanoparticles made of iron oxide, gold, quantum dots or metal oxide frameworks \[[@r46]-[@r48]\].

The tumor vasculature is structurally and functionally abnormal \[[@r49]\]. The vessels spread chaotically with abnormally varied caliber, and the smooth muscle layer is not correctly formed. Hence vascular walls contain wide fenestrations \[[@r50]-[@r53]\]. Furthermore, tumor tissues have ineffici- ent lymphatic drainage \[[@r54]\]. A significant number of vessels make shunts between arterial and venous ends, effectively stealing blood from regions of the tumor tissue and inducing localized hypoxia \[[@r53], [@r55], [@r56]\].

This leaky tumor vasculature, slow venous return and poor lymphatic clearance lead to the accumulation of macromolecules within the tumor, and this phenomenon was termed the enhanced permeability and retention (EPR) effect of macromolecules (larger than 7 nm) by Maeda and colleagues \[[@r57]\].

Despite the remarkable advances in DDS based on EPR, a limited number of nanocarriers have reached the clinic so far \[[@r58]\]. In this context, one major challenge is the lack of an EPR effect for macromolecules in the hypoxic area of tumors, particularly the necrotic regions of primary and metastatic cancers \[[@r59], [@r60]\]. Therefore extensive efforts have been made to increase the EPR effect in tumor tissue \[[@r61]\].

Several factors affecting vascular permeability have been investigated, including: vascular endo- thelial growth factors, bradykinin, prostaglandins and NO \[[@r62]\], as any intervention which enhances tumor blood supply should increase the EPR effect of macromolecules. For example, the NOS inhibitor *N*^ω^-monomethyl-l-arginine (NMMG), was shown to suppress vascular permeability and hence the EPR effect \[[@r63]\], while NO donors have been found to potentiate the EPR effect. Examples of potentiation include the local administration of the NO donor GTN directly into tumor sites, which increased the concentration of PEG-conjugated zinc protoporphyrin IX anticancer NPs, indicating an elevated EPR effect and thereby improved delivery of the drug to the tumor \[[@r64]\]. Similarly, infusion of isosorbide dinitrate (ISDN) into the local feeding artery of tumours enhanced the site-specific delivery of anticancer NPs in humans \[[@r61]\].

EPR enhancement can also be achived by elevating blood pressure, as this will increase tumor blood flow \[[@r59]\], and several clinical studies have used NO donors such as GTN to improve the responsiveness of tumors to chemo and/or radiotherapy (Table **[1](#T1){ref-type="table"}**). On the other hand, the systemic administration of unstable NO donors may result in a significant decrease in systemic blood pressure thereby decreasing the EPR effect \[[@r59]\]. Therefore, the utility of NO donors to enhance the EPR effect in solid tumors, or to reach a tumorcidal level of NO, is highly dependent of the stability of the NO donors.

In addition, as mentioned above, NO acts differently over a range of concentrations within the tumor, and therefore it must be delivered at a designated concentration to tumor cells. Hence, the development of stable and tuned NO releasing compounds are required for applications towards tumor therapy. In the following sections we initially review the NO donor moieties which can be used for controlled delivery of NO, and then focus on recent developments in the controled delivery of NO using NO releasing macromole- cules for tumor therapy.

5. MAJOR CLASSES OF NO DONORS {#sec5}
=============================

There are at least 16 families of NO precursor and direct NO donors with remarkably varied chemical reactivities and NO-release kinetics. However, organic nitrates, organic nitrites, metal complexes, sydnonimines, diazeniumdiolates, and S-nitrosothiols are the major groups used in experimental and clinical applications.

5.1. L-Arginine and N-Hydroxyguanidine {#sec5.1}
--------------------------------------

NO is synthesized *via* conversion of L-arginine to NO and citrulline by the NOS family (Scheme **[1](#S1){ref-type="scheme"}**). There are three different NOS isoforms in mammalian organisms: neuronal (nNOS), inducible (iNOS), and endothelial NOS (eNOS). The isoforms have similar mechanisms for NO synthesis however, their distribution in different cell types, and their mechanism of activation, are different \[[@r65]\]. nNOS and eNOS are mainly expressed in neuronal and endothelial cells respectively, but iNOS is expressed in both endothelial as well as nonvascular cell types such as macrophages, fibroblasts, and hepatocytes \[[@r66]\]. A major functional difference between NOS isoforms is that the activity of iNOS is initiated in response to inflammatory mediators and the expression of iNOS in healthy states is absent. Therefore, the activity of iNOS is subject to protein transcription, and the expression of iNOS has been shown to be a detrimental player in the development of disease. Whereas eNOS is constitutively active and regulates physiological processes such as vasodilation \[[@r66]\].

Although it is not an actual NO donor, L-arginine administration has been widely used to increase NO generation. For example, it displays beneficial properties in stroke \[[@r67], [@r68]\], angiogen- esis \[[@r69]\] and wound healing \[[@r70]\]. The biosyn- thesis of NO is an oxygen dependent pathway, and so analogues of the intermediate generated during NO synthesis, the N-hydroxyguanidines such as ω-hydroxy-L-arginine (NHA) \[[@r2]\], have been used as an alternative for L-arginine delivery \[[@r71]\]. This family is particularly important in the treatment of hypoxic conditions such as stroke, as converting NHA to NO can occur at low oxygen concentra- tions \[[@r72]\].

5.2. Organic Nitrates {#sec5.2}
---------------------

Organic nitrates (RONO~2~) are nitric acid esters of alcohols. They are the oldest class of NO donors and currently the most commonly used NO donor drugs \[[@r73]\]. Organic nitrates can be synthe- sized by esterification of the corresponding alco- hols, or by the reaction of alkyl halides with AgNO~3~ (Scheme **[2](#S2){ref-type="scheme"}**) \[[@r2]\]. GTN, isosorbide mononitrate (ISMN), pentaerythritol tetranitrate (PETN) and nicorandil are the most wildly used exampes in clinical studies. Most organic nitrates are highly stable, and the mechanism by which they release NO is not fully understood. However, it has been suggested that the NO formation can happen *via* both enzyme-dependent and non-enzymatic pathways \[[@r2]\]. Several enzymes such as NADPH-dependent cytochrome P450 \[[@r74], [@r75]\] and certain isoenzymes of the glutathione-*S*-transferase (GST) family \[[@r76]\] have been recognized in the bio-activation of organic nitrates. It has been shown that thiols significantly affect both *in vitro*

and *in vivo* responses to GTN by promoting its NO release \[[@r77], [@r78]\] however these reactions are much slower than enzymatic activation. Therefore the dependency on enzymatic reaction to liberate NO is a major drawback to the clinical use of these drugs, as tolerance develops over time \[[@r79]\].

The organic nitrates have several established clinical applications. GTN is used as a cheap and effective drug for the rapid reversal of pain associated with acute angina \[[@r80], [@r81]\], and also occasionally for heart failure \[[@r82]\]. ISMN, which is a slower NO-releasing member of the organic nitrate family, has been used in the treatment of chronic angina \[[@r83]\]. As well as providing rapid and sustained dilation of veins, reducing cardiac afterload work, it causes dilation of cardiac vessels, which restores oxygen supply to ischemic cardiac muscle.

5.3. Organic Nitrites {#sec5.3}
---------------------

Analogous to nitrates, organic nitrites are esters of alcohols and nitrous acid. They are mainly synthesized *via* reacting alcohols with nitrous acid or other nitrosating agents, as well as by the reaction of alcohols with gaseous NO (Scheme **[3](#S3){ref-type="scheme"}**) \[[@r2]\]. The nitrosyl nitrogen atoms in organic nitrites are highly electronegative, which results in electron deficiency, hence they are highly prone to nucleophilic attack, which results in trans-nitrosation between the organic nitrite and the nucleophile \[[@r84]\]. Butyl nitrite (BN), isobutyl nitrite (ISBN), *tert*-butyl nitrite (TBN), amyl nitrite (AMN), and isoamyl nitrite (IAMN) have been used as vasodilators in the clinic.

It has been shown that organic nitrites activate NO signalling pathways, relaxing pulmonary vessels and decreasing blood pressure \[[@r85]\]. The release of NO from organic nitrites can occur through S-nitrosothiol formation due to the very fast trans-nitrosation with sulfhydryl groups \[[@r84]\]. Despite the higher potency of organic nitrites (as they are more reactive and less dependent on enzymatic activation) they are not as commonly used as organic nitrates due to their cytotoxicity \[[@r2]\], however AMN and BN have frequently been used in the treatment of angina pectoris \[[@r86]\]. The advantage of the organic nitrites is that they are less susceptible to inducing drug tolerance in comparison to organic nitrates such as GTN \[[@r87]\]. However a lack of selectivity and bioavailability, as well as cytotoxicity and carcinogenicity, restrict the applications of this class of NO donor \[[@r86]\].

5.4. Metal Complexes {#sec5.4}
--------------------

NO is a strong ligand in metal complexes, and its binding constant is normally much higher than those of CO and O~2~ \[[@r88]\]. Numerous metal centers (primarily iron) react with NO to give adducts (Scheme **[4](#S4){ref-type="scheme"}**), and the primary mechanism by which NO regulates many signaling pathways is through binding to metal centers, such as the haem group or iron-sulfur clusters of proteins. NO, as a ligand in metal complexes, has various oxidation states from M-NO^-^ to M-NO^+^ and the oxidation state determines the reactivity of NO in the complex \[[@r89]\]. For example NO in sodium nitroprusside (SNP, Na~2~\[Fe(CN)~5~NO\]) exhibits significant NO^+^ character and iron has an oxidation state of Fe^3+^. The NO ligand is therefore subject to nucleophilic attack, hence the rate of NO release from SNP can be affected by thiols and other potential nucleophiles in the environment.

SNP was the first metal-NO compound discovered over 150 years ago, and has been in widespread clinical use for 40 years \[[@r90]\]. SNP is used as an arterial and venous vasodilator in cardiac surgery, hypertensive crisis, heart failure, vascular surgery, and pediatric surgery \[[@r91]\]. However SNP degradation is accompanied by five equivalents of cyanide release, which results in "cyanide toxicity" \[[@r91]\]. This dose limiting toxicity of cyanide release has been well-documented in several clinical cases and animal studies and precludes long term administration \[[@r92], [@r93]\].

In addition to iron, ruthenium (Ru) also has a high affinity for NO, and this has resulted in the development of a family of photoactive NO-releasing Ru complexes \[[@r94]\]. By modification of the π-bonding of other ligands, the affinity of Ru for NO can be modified, thereby regulating NO release from the complex \[[@r95]\]. Several photoactive Ru nitrosyls have been tested in *in vitro* and *in vivo* studies for controlled NO delivery \[[@r96]\]. However, efficient NO release requires high power UV light (300-400 nm) which is harmful to tissues \[[@r94]\] and this hurdle has prevented the translation of this family of NO donors into clinical use.

5.5. Diazeniumdiolates {#sec5.5}
----------------------

The diazeniumdiolates (also known as 'NONOates') consist of a diolate group attached to a primary or secondary amine or polyamine. In solid form they are stable, but decompose sponta- neously in solution at physiological pH and tem- perature to generate two equivalents of NO per diolate \[[@r97]\]. They can be simply synthesized by exposing a primary or secondary amine to NO under high pressure \[[@r98]\], and depending on the structure of parent amine, temperature, and pH, their decomposition rates vary from seconds to hours \[[@r99]\]. Unlike most other NO donors, the NO release of diazeniumdiolates is not catalyzed by cellular metabolites or enzymes, and follows first-order kinetics. Hence the duration of action of the drugs can be directly predicted from their rates of decomposition *in vitro*. In addition, independent NO release explains the lack of tolerance experi- enced with these compounds \[[@r100]\]. Some of the most studied NONOates are methylamine hexa- methylene methylamine NONOate (MAHMA/ NO), diethylamine NONOate (DEA/NO), sper- mine NONOate (SPER/NO), proli NONOate (PROLI/NO) and diethylenetriamine NONOate (DETA/NO) (Scheme **[5](#S5){ref-type="scheme"}**). No drug from this class of NO donors has advanced to clinical stages, however, they have frequently been tested in various experimental models of cardiovascular disease \[[@r97]\] mainly as supplementary treatments for vital cardiovascular operations such as balloon angioplasty and bypass, to prevent thrombosis and neointimal formation \[[@r101]-[@r105]\].

5.6. Sydnonimines {#sec5.6}
-----------------

Sydnonimines are another class of NO releasing agents which, due to the concomitant generation of O~2~^•-^ and NO, are recognized as an ONOO^-^ donors \[[@r106], [@r107]\]. In general, sydnonimines are synthe- sized by α-cyanoalkylation of dialkylhydrazines followed by nitrosation under acidic conditions (Scheme **[6](#S6){ref-type="scheme"}**). 3-morpholinosydnonimine (SIN-1) and its precursor molsidomine (N-ethoxycarbonyl-3-morpholinosydnonimine) are the most exten-

sively studied compounds of this class. N-acyl derivatives of sydnonimines in solid form are stable and in the absence of light can be kept at room temperature. Sydnonimines can be degraded by both enzymatic and nonenzymatic processes at physiological pH. Nonenzymatic hydrolysis is accelerated by alkaline pH, the presence of O~2~, and light. The enzymatic deacetylation and conversion of molsidomine to SIN-1 occurs primarily in the liver, SIN-1 then spontaneously decomposes to NO and O~2~^•-^ in the blood \[[@r108], [@r109]\]. As ONOO^-^ is highly reactive, it is believed that many of the actions of sydnonimines are mediated *via* cGMP-independent pathways, and possibly activation of K^+^ channels \[[@r110]\]. One of the main advantages of molsidomines as NO donors is the absence of tolerance. Hence, in the early 1980s, sydnonimines were widely studied as alternatives to organic nitrates in stable angina, and in the treatment of coronary heart disease \[[@r109]\]. However, they failed to show clear benefit in many large-scale clinical trials \[[@r111]\].

5.7. S-nitrosothiols {#sec5.7}
--------------------

S-nitrosothiols (SNTs), also known as thionitrites, are an important class of NO donor which are mainly synthesized by the reaction of a thiol with a nitrite. SNTs, with certain exceptions, are very unstable compounds in aqueous solution, especially the primary and secondary SNTs \[[@r112]\]. Degradation of SNTs involves both homolytic and heterolytic cleavage of the S-NO bond \[[@r113]\] which results in the corresponding disulfide and NO, NO^+^ or NO^-^ (Scheme **[7](#S7){ref-type="scheme"}**). Homolytic cleavage is a two-step reaction which starts by cleavage of S-NO bond to make the thiyl radical (RS^•^), followed by reaction of two RS^•^ radicals to form a disulfide (RSSR) \[[@r114]\]. One of the main reasons why tertiary SNTs are more stable than primary and secondary analogues could be due to the easier dimerization of the less sterically hindered RS^•^. The degradation of SNTs may also occur through trans-nitrosation to other nucleophilic species, such as thiols, without the appearance of NO as a free entity \[[@r113]\].

The instability of SNTs *in vivo* is more pronounced, as their degradation rate is accelerated by vitamin C, trace amounts of metal ions, thiols such as GSH, and oxygen, as well as by enzymatic cleavage.

S-nitrosoglutathione (GSNO), N-acetylpenicill- amine (SNAP), trityl S-nitrosothiol, (Ph~3~SNO) and tert-butyl S-nitrosothiol (tButSNO) are the most commonly studied SNTs \[[@r114]\], alongside the recently developed tert-dodecane S-nitrosothiol (tDodSNO) \[[@r115]\] (Scheme **[7](#S7){ref-type="scheme"}**).

5.8. Other NO-Releasing Moieties {#sec5.8}
--------------------------------

N-nitrosamine, N-hydroxy nitrosamine, nitrosi- mine, furoxan and oximes are other functional groups which can serve as NO releasing moieties. However the majority of studies still rely upon the six main classes of NO donors.

One of the most important drugs which con- tains the N-nitrosamine group is *N*-methyl-*N*-nitrosourea streptozocin (STZ), which has antitumor as well as diabetogenic and carcinogenic activities \[[@r2]\]. NO release by STZ in the pancreatic β cell is known as one of the central mecha- nisms for these properties \[[@r116]\]. β cells of the pancreas are sensitive to NO and ROS as they possess low levels of ROS scavenging enzymes \[[@r117]\], and overproduction of NO damages the DNA content of the cells. *N*-hydroxy-*N*-nitrosamines are potent anti-hypertensive and anti-coagulative agents which are heat-stable in solution. Cupferron, alanosine, and dopastin are the most studied compounds in this class of NO donor, which have mainly been investigated as anticancer drugs \[[@r118]\].

Furoxans generally are stable compounds against thermal degradation, acids and electrophiles but not toward bases and nucleophiles \[[@r2]\]. Their deg- radation and NO release take place in the presence of thiols. They currently have no clinical application, but in animal studies, some furoxans such as C92-4609, and C93-4759 displayed tolerance-resistant vasodilation \[[@r119], [@r120]\].

6. Hybrid NO-releasing anticancer drugs {#sec6}
=======================================

Due to the diverse activity of NO in bio- logical processes, as well as the complexity of NO delivery to tumor tissue, low molecular weight NO releasing compounds have made limited progress for tumor treatment so far. In particular, short half-lives, non-specific NO release, and rapid systemic clearance have hindered the clinical development of most NO donor compounds as anticancer drugs. However, there has been an extensive effort to develop hybrid NO donor drugs by attachment of NO donor moieties to currently available anti- cancer drugs to maintain the pharmacological activity of the parent drug, while gaining benefit from the biological actions of NO \[[@r121]\]. To get the desired biological activity (such as anticancer action) from NO release in the hybrid, the ratio of the parent drug to NO equivalents released can be varied \[[@r122]\]. The most commonly used NO releasing moieties for the design of hybrid drugs are S-nitrosothiols, diazeniumdiolates, furoxans, and organic nitrates.

NO releasing versions of NSAIDs have been used for cancer therapy. For example, several NO releasing hybrids of aspirin have been designed using furoxan \[[@r123]\], nitrate and S-nitrosothiol moieties \[[@r124]\]. NCX4040, synthesized by esterifi- cation of the carboxyl group of aspirin with 4-hydroxybenzyl nitrate (Scheme **[8](#S8){ref-type="scheme"}**) showed 250-6,000-fold greater efficacy at inhibiting the growth of a panel of cancer cell lines \[[@r125]\]. NO releasing topoisomerase inhibitors have also been synthe- sized by conjugation of the anticancer drug doxorubicin (Dox) with a phenylsulfonyl furoxan moiety (NO-DOXO-1). These Dox analogs were

shown to accumulate in Dox resistant human colon cancer cells (HT29-dx), and resulted in high cytotoxicity \[[@r126]\]. The same group has recently designed a novel light responsive NO releasing Dox to overcome multidrug resistance using a derivative of 4-nitro-3-(trifluoromethyl)aniline (NO-DOXO-2**)** \[[@r127]\].

The acetylation status of histones regulates levels of gene expression, and overexpression of histone deacetylases (HDAC) is oberved in nume- rous types of cancer. Hence, HDAC inhibitors have been suggested as a promising agents for cancer therapy \[[@r128]\]. The antiproliferative activity of a NO releasing HDAC inhibitor (Scheme **[8](#S8){ref-type="scheme"}**) has been reported as a superior version of vorinostat, a HDAC inhibitor drug, against the human erythro- leukemia (HEL) cell line \[[@r129]\].

7. NO-RELEASING MACROMOLECULES {#sec7}
==============================

As mentioned above, so far very few low molecular weight NO releasing drugs have been used for cancer therapy whose main mechanism of action is through NO donation. Hence, in response to the need for controlled NO delivery, there has been extensive effort to design macromolecular NO-releasing vehicles \[[@r130]-[@r132]\]. In the following section we review the biomaterials which have been used for controlled delivery of NO particularly for cancer therapy (a few recent studies are summarized in Table **[2](#T2){ref-type="table"}**).

7.1. Encapsulation of Gaseous NO or Low Molecular Weight NO Donors {#sec7.1}
------------------------------------------------------------------

One of the initial strategies was direct encapsulation of NO gas as an active therapeutic. Perfluorocarbon (PFC) microbubbles are emulsions of synthetic hydrophobic fluorinated hydrocarbons and surfactants which can store large amounts of O~2~ and NO \[[@r133]\]. These emulsions are biologically inactive and can be safely injected into the vascular system \[[@r134]\]. It has been shown that PFC long-circulating particles can provide a physiologically significant pool of endogenous plasma NO, which can be used as a pharmacological tool for various cardiovascular complications associated with NO imbalance \[[@r135]\]. Polymeric carriers such as poly (vinyl alcohol) shelled NO microbubbles \[[@r136]\] and liposome encapsulations of gaseous NO \[[@r137]\] have also been investigated as NO delivery systems. Nevertheless, NO gas encapsulations are unstable and gaining control over their NO release is difficult.

Another strategy for controlled NO delivery is via the encapsulation of NO donor drugs. Here the potential advantage is that the NO donor remains trapped within the particle, avoiding unwanted cytotoxicity. For example a ruthenium nitrosyl complex was embedded in a poly-lactic-co-glycolic acid (PLGA) matrix, from which only NO release was observed with no leakage of the remaining metal fragment \[[@r138], [@r139]\].

Unlike encapsulation of gaseous NO, NO release from encapsulated NO donors is sensitive to environment, and the presence of water, vitamin C and GSH may affect the rate of NO release from the particle \[[@r130]\]. Recently Schoenfisch's group has reported encapsulation of a *N*-diazeniumdio- late in liposomal structures. The NO release of the system could be precisely controlled by varying the composition of the lipid layer \[[@r140]\]. PROLI/NO, DEA/NO, PAPA/NO, or SPER/NO have been encapsulated in such phospholipid bilayers to form different NO-releasing liposomes \[[@r140]\]. The encapsulation process significantly increased the t~1/2~ of the NO donors, for example, t~1/2~ of SPER/NO increased from 37 min in its free form to around 2 days when encapsulated within the liposome. The physical barrier against proton diffusion/exchange provided by the lipid bilayer was demonstrated to be the main mechanism for the prolonged NO release properties of the liposomes. Interestingly, the NO-release kinetics of different liposomes with identical NO donors was dependent on the compactness of the lipid chains of each individual liposome, which is a property set upon liposome formation \[[@r140]\]. Therefore, by manipulation of the structure of lipid bilayer, the water permeability of the liposomes and hence the kinetics of NO release could be tuned, with tighter packing of the lipid chains decreasing the *N*-diazeniumdiolate NO donor decomposition rate Fig. (**[3](#F3){ref-type="fig"}**) \[[@r140], [@r141]\].

Recently we have designed a photoactive NO releasing nanoparticle (NP) by encapsulation of the S-nitrosothiol tDodSNO into a co-polymer of styrene and maleic acid (SMA) to afford SMA-tDodSNO. The encapsulation imparted water solubility to the highly hydrophobic tDodSNO, and protected it from degradation reactions with glutathione \[[@r142], [@r143]\]. In the absence of photoactivation, the S-nitrosothiol group within the NPs had a t~1/2~ of 104 h, while photoactivation dropped this to 3.5 min. The NPs acted as a photo-switchable NO donor and induced localized vasodilation in aortic rings, and vascular hyperpermeability in mesenteric beds. When SMA-tDodSNO was co-adminis- tered with SMA-Dox (SMA NPs loaded with doxorubicin) it significantly enhanced its anticancer properties \[[@r144]\].

In addition, it has been shown that encapsulation of low molecular weight NONOates in liposomes improves the tumor targeting of such NO donors due to the EPR effects of the NPs \[[@r145]\], and administration of such NO releasing NPs with anticancer drugs increases their anticancer efficacy \[[@r144], [@r145]\].

7.2. Polymeric Organic and Inorganic NO Releasing Scaffolds {#sec7.2}
-----------------------------------------------------------

In addition, to improve the control of NO release in biological media, a wide-variety of NO donor materials such as macromolecule scaffolds, polymeric NPs, micelles, dendrimers, sol-gel derived silica NPs and surface modified metal/metal oxide NPs have been examined as NO delivery systems \[[@r130], [@r146]\]. These polymeric NO donors have been examined as treatments for a large number of pathological conditions ranging from cardiovascular diseases, wound healing, neuropathy and stroke to cancer \[[@r131], [@r147]\].

As an example of this approach, analysis of the tumor microenvironment of solid tumors has revealed that a significant part of the tumor mass is made of immune cells. Hence, tumor immune cells have been characterized as suitable targets for tumor therapy \[[@r148]\]. In immune cells iNOS produces high concentrations of NO, so it is possible to achieve a higher concentration of NO in tumor tissue by delivering arginine to the immune cells of the tumor \[[@r149]\]. Therefore there has been increasing interest in the application of poly-arginine for tumor targeting.

Kudo *et al*. have designed polyion complex micelles from a poly(ethylene glycol)-block-poly(l-arginine) block copolymer (PEG-*b*-PArg) and chondroitin sulfate for systemic anticancer immunotherapy \[[@r149]\] Fig. **[4](#F4){ref-type="fig"}**. Without activation the NPs did not generate NO when exposed to iNOS *in vitro*. After trypsin pretreatment and hydrolysis of the polymeric Arg to monomeric arginine, iNOS exposure then resulted in NO generation. Therefore the activation of the NPs required enzymatic degradation to monomeric arginine in the lysosomes of immune or cancer cells in tumor tissue. Hence, the systemic administration of the NPs did not induce any tangible adverse effects. However they did significantly suppressed tumor growth rate in a dose-dependent manner \[[@r149]\].

The pivotal role of albumin in the circulation of NO in the plasma has been well established \[[@r150]\]. Human serum albumin (HSA) has one site of S-nitrosation at the Cys-34 thiol, which can carry NO equivalents in the circulatory system in the form of an S-nitrosothiol \[[@r150]\]. S-nitrosated HSA (HSASNO) has significantly superior stability compared with low molecular weight SNTs \[[@r151]\]. In numerous studies HSA has been used as a long-acting and safe NO donor for several pathological conditions including cancer (this has been recently reviewed \[[@r151]\]). As it only has one S-NO group HSASNO produced low levels of NO (nM range) when administered at physiological levels mimicking HSA in blood, therefore under pathological conditions it acts as a cytoprotective agent as it produces low concentrations of NO. To improve its NO release properties HSA has been chemically modified by attachment of linkers and then binding to low molecular weight SNTs to form poly-HSASNO. Here two HSA molecules were linked together using the amino acid linker (GGGGS)~2~ to form a HAS-dimer which had a significantly longer circulation time than the mono-

meric form of HSA \[[@r152]\]. It has been shown that the HSA-dimer had an enhanced accumulation in solid tumors *via* an increased EPR effect \[[@r153]\] Fig. **[5](#F5){ref-type="fig"}** . Nitrosation of the HSA-dimer resulted in NO releasing NPs (SNO-HSA-dimer), which also further enhanced its EPR effect in tumors \[[@r153]\], as well as other anti-cancer loaded NPs. In xenograft mice with B16 or C26 tumors, the SNO-HSA-dimer increased tumor accumulation of the anti-cancer agents N-(2-hydroxypropyl) methacrylamide (HPMA)-zinc protoporphyrin (ZnPP) and PEGylated liposomal doxorubicin (Doxil) compared with only NnPP or Doxil treated mice (by a factor of 3-4 in C26 tumors and 6 in B16 tumors), and thereby enhanced the anticancer efficacy of these drugs Fig. **[6](#F6){ref-type="fig"}** , and increased survival of the animals \[[@r154]\]. The administration of SNO-HSA-dimer itself was found to be safe in the animals, as it did not affect blood pressure or heart rate.

In 2002 the first microparticle formed from an NO releasing polymer was reported by the Meyerhoff group \[[@r155]\]. The group deployed methyl methacrylate as an amine bearing monomer, and utilized 1,6-hexanedioldimethacrylate as a reactive cross-linker to form polymeric microbeads. The secondary amine groups were then converted to diazeniumdiolates to form NO releasing particles with a size of 100-200 µm. The particles had t~1/2~ values for NO release ranging from 30 to 60 min when suspended in PBS \[[@r155]\]. Following this initial work there has been an extensive effort to develop tunable release polymers for the controlled delivery of NO. For example GSNO was covalently attached to a diblock copolymer made from the polymerization of oligoethylene glycol-methacry- late (OEG-MA) and (4-cyanopentanoic acid)-4-dithiobenzoate to afford an NO releasing polymer, which in aqueous environments self-assembled and made nano-sized micelles. The polymeric NPs improved the stability of GSNO (3.5 fold) without affecting the efficacy of intracellular delivery. Additionally, in the presence of ascorbic acid, the t~1/2~ of the NPs was significantly longer than the GSNO alone, demonstrating protection from S-nitrosothiol degradation pathways. When neuroblastoma cells were pre-treated with these NO releasing NPs they were significantly more sensitive to cisplatin treatment, with a 5-fold shift in IC~50~.

The use of dendrimers for controlled NO delivery was first described by the Schoenfisch group \[[@r156]\]. They used the commercially available generation 3 and 5 polypropylenimine dendrimers, and reacted then with high pressure gaseous NO (5 atm) to form NONOate dendrimers. NONOate

dendrimers generated from primary amines were not effective in providing sustained release of NO. However secondary amine NONOate dendrimers showed a high storage capacity for NO, and the release durations were significantly longer compared to small molecule alkyl secondary amine NONOates; however, the t~1/2~ of most of the NO releasing dendrimers were less than 2 h \[[@r156]\]. In another study from the same group, generation 4 polyamidoamine (PAMAM) dendrimers were functionalized with either SNAP or N-acetyl-L-cysteine to yield thiol terminated dendrimers, then converted to SNT terminated dendrimers \[[@r157]\]. Similarly to low molecular weight SNTs, the kinetics of NO release were found to be highly sensitive to Cu^+^ and photoactivation. The SNAP-dendrimer was particularly effective, showing 62% inhibition of platelet aggregation, which was almost 3 times greater than SNAP alone \[[@r157]\].

Gold nanoparticles (GNPs) have been widely used as non-toxic carriers in drug and gene delivery systems \[[@r158]\]. The inert and non-toxic gold core \[[@r159]\] and facile synthesis of GNPs make them very popular agents for drug delivery \[[@r158]\]. Rothrock *et al*. initially used GNPs for the controlled delivery of NO \[[@r160]\]. The synthesis strategy is shown in Fig. **[7](#F7){ref-type="fig"}** , approximately 2 nm diameter GNPs were made by reduction of tetrachloroaurate (AuCl~4~^-^) with sodium citrate or sodium borohydride in the presence of hexanethiol ligands. Then the ligands were exchanged with bromoalkane thiols, followed by reaction with ethylenediamine, butylamine or hexanediamine. When the GNPs (functionalized with a primary or secondary amine) were exposed to high pressure gaseous NO, the final NO-releasing NPs were generated \[[@r160]\]. Theoretically an advantage of these NO releasing NPs is the ability to control both the amount of loaded NO, and the kinetics of NO release, by modification of the amount and/or structure of amine groups in the NPs \[[@r130]\]. However, due to the poor NO storage capacity and low solubility in aqueous media, the application of this class of NO-releasing NPs is limited \[[@r130]\].

Zeolites are aluminosilicate minerals which contain a variety of pore sizes and shapes \[[@r161]\], while metal-organic frameworks (MOFs) are a polymeric material consisting of metal ions bridged by organic ligands \[[@r162]\]. These classes of highly porous materials have been widely used for ion exchange, catalysis, and gas adsorption \[[@r161], [@r162]\]. The chemical characteristics of these materials, especially nano-scaled systems, make them potentially suitable for medical applications including the delivery of NO \[[@r163]\]. In zeolites, NO is chemisorbed to the cationic centers of the crystals \[[@r130]\], while in MOFs it can chemisorb to either the cationic centers or the organic structure of the framework. MOFs are well known for their high porosity and large surface areas, which gives them the capability of storing and delivering gases such as NO *via* physiosorbing (physically trapping) within their pores \[[@r164], [@r165]\]. The physiochemical properties of MOFs (such as the level of porosity) can remarkably affect their control over NO delivery \[[@r166]-[@r168]\]. In general, the biomedical application of most zeolites and MOFs is restricted due to their low water solubility and instability \[[@r130]\].

More recently, stimuli responsive NO delivery has been utilized to control NO release on demand and in tumor tissue. For example, light responsive NO releasing NPs were made from the encapsulation of N,N′-di-sec-butyl-N,N′-dinitroso-1,4-phe- nylenediamine (BNN6), a NO releasing molecule, Dox and a mPEG-PLGA copolymer Fig. **[8](#F8){ref-type="fig"}** \[[@r169]\]. Upon the irradiation by UV light the NO content of BNN6 was released, and the generated NO gas broke the nanoparticle shell and led to the release of Dox. Hence, the release of both NO and Dox was responsive to UV irradiation. Incubation of OVCAR-8/ADR cells with the NPs resulted in a higher intracellular concentration of Dox compared to the equivalent treatment with free Dox, potentially due to NO release from the NPs inhibiting MDR \[[@r169]\]. In addition, other sources of energies (*e.g*. NIR, X rays and ultrasound) have been used to tune the NO release and anticancer properties of the NPs \[[@r170]-[@r172]\] as summarized in Table **[](#T1){ref-type="table"}**.

CONCLUSION AND FUTURE PERSPECTIVES
==================================

As detailed above, NO plays a key role in tumor biology and therapy, and there are several approaches that have been utilized to induce antitumor activities, or improve the efficacy of chemotherapy and radiotherapy, from NO releasing compounds. So far at least 16 families of NO precursor and NO donor functional groups have been developed. However only organic nitrates and SNP have clinical applications, predominantly for cardiovascular disease. Hence the development of stable and tuned NO donor compounds is a priority for drug discovery programs. Nanotechnology has revolutionized the NO delivery field, and the level of interest in NO releasing NPs has exploded over last decade. By protecting polymers carrying NO releasing functional groups from hydrolysis, researchers have developed stable and controllable NO donors with superior biological functions, paving the way for their therapeutic applications towards a wide range of diseases including cancer.

However, the controlled delivery of cytotoxic levels of NO to tumor tissues remains a major challenge. Therefore, similarly to the hybrid NO donor drugs, investigations into NO releasing NPs have recently shifted to using them as an approach to strengthen the efficacy of existing drugs. Here NO delivery can inhibit MDR and potentiate the efficacy of chemotherapeutic drugs (recently reviewed \[[@r173]-[@r183]\]). Furthermore, the use of NO releasing nanocarriers can sensitize hypoxic cells to radiation, circumventing radiation resistance, which is a major hurdle in treating solid tumors \[[@r127]\].
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![The direct and indirect effects of NO in cell signaling. The interaction of NO with O~2~ and O~2~^.-^ results in species such as N~2~O~3~ and ONOO^-^, which modulate some of the biological activities of NO such as DNA damage and lipid peroxidation.](PNT-7-279_F1){#F1}

![The effect of sustained levels of NO on signal transduction mechanisms in cancer cells. These data were generated by treating cancer cells with diethylenetriamine NONOate (DETA/NO) for 24 h, then the activation of specific pathways was evaluated \[[@r30]-[@r32]\].](PNT-7-279_F2){#F2}

![The encapsulation of N-diazeniumdiolates in liposomal structures. The stability of the NO donors was significantly enhanced when encapsulated in the liposomes. In addition, NO release from the liposomes could be regulated by altering the NO donor molecular structure, or the phospholipid composition of the liposome (independently or in combination) \[[@r137]\]. By changing the composition of the phospholipid layer from highly dense (left) to loosely packed (right), the stability of the NO releasing liposome dramatically decreased.](PNT-7-279_F3){#F3}

![Schematic illustration of polyionic NPs made from PEG-*b*-PArg and chondroitin sulfate for systemic anticancer immunotherapy \[[@r145]\]. The L-arginine moiety is highlighted (blue). (*The color version of the figure is available in the electronic copy of the article*).](PNT-7-279_F4){#F4}

![The synthesis of NO-releasing micelles(black/blue) using GSNO (red) for synergistic cytotoxicity against cancer cells \[[@r146]\]. (*The color version of the figure is available in the electronic copy of the article*).](PNT-7-279_F5){#F5}

![The NO releasing NP SNO-HSA-dimer enhanced the EPR effect of macromolecules in tumor tissue, and hence augmented the anti-tumor effects of the Dox loaded NP Doxil.](PNT-7-279_F6){#F6}

![NO releasing gold NPs. HAuCl~4~ was reduced by sodium borohydride in the presence of an alkylthiol, and the ligand then exchanged and chemically modified to make the NO releasing NPs \[[@r154]\].](PNT-7-279_F7){#F7}

![BNN6 is a NO releasing micelle which contains Dox. Upon photo-irradiation NO was released from BNN6, the nanoparticle shell broken, and Dox then released. In addition, the released NO significantly inhibited MDR (p-glycoprotein) and thereby resistance to Dox.](PNT-7-279_F8){#F8}

![The mechanism of NO biosynthesis.](PNT-7-279_S1){#S1}

![Some examples of the most commonly used organic nitrates and their general mechanism of synthesis. The nitrate group is highlighted (blue). (*The color version of the figure is available in the electronic copy of the article*).](PNT-7-279_S2){#S2}

![Chemical structures of common organic nitrites and their mechanism of synthesis. The nitrite group is highlighted (blue). (*The color version of the figure is available in the electronic copy of the article*).](PNT-7-279_S3){#S3}

![Example structures of NO releasing metal complexes, and the mechanism of SNP synthesis.](PNT-7-279_S4){#S4}

![Chemical structures of representative NONOates and their mechanism of synthesis. The diazeniumdiolate moiety is highlighted (blue). (*The color version of the figure is available in the electronic copy of the article*).](PNT-7-279_S5){#S5}

![Chemical structures of sydnonimines and their mechanism of synthesis.](PNT-7-279_S6){#S6}

![Chemical structures of common SNTs, and the mechanisms of SNT decomposition. NO releasing moieties are highlighted (tertiary SNT, green; primary SNT, red). (*The color version of the figure is available in the electronic copy of the article*).](PNT-7-279_S7){#S7}

![Example structures of hybrid NO releasing anticancer drugs. The parent drug (black) can be modified by NO releasing moieties (blue) and linker groups (red). (*The color version of the figure is available in the electronic copy of the article*).](PNT-7-279_S8){#S8}

###### Example clinical studies which used NO donors to improve the effects of chemo and/or radiotherapy.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Drug**                                             **NO Donor**         **Type of the Study**     **Cancer Type**              **Results**                                                                                      **References**
  ---------------------------------------------------- -------------------- ------------------------- ---------------------------- ------------------------------------------------------------------------------------------------ ----------------------
  Cisplatin and\                                       Isosorbide\          Phase II clinical trial   Non-small cell lung cancer   ISMN did not improve the treatment outcome of the chemotherapy                                   \[[@r174]\]
  irinotecan                                           mononitrate (ISMN)                                                                                                                                                           

  5-FU and radiation                                   GTN patch            Phase I clinical trial    Lung cancer                  The patches were well-tolerated and significantly enhanced the\                                  \[[@r175]\]
                                                                                                                                   efficacy of the treatment.                                                                       

  Combination of\                                      GTN                  Phase II clinical trial   Non-small cell lung cancer   Improve overall response in patients with stage IIIB/IV NSCLC patients                           \[[@r176]\]
  vinorelbine and\                                                                                                                                                                                                                  
  cisplatin                                                                                                                                                                                                                         

  Vinorelbine, cisplatin and concurrent radiotherapy   GTN patch            Phase II clinical trial   Non-small cell lung cancer   Increase in the overall survival of compared patient after 2 years                               \[[@r177], [@r178]\]

  Prostate-specific\                                   GTN patch            Phase II clinical trial   Prostate cancer              Significantly (p\<0.001) longer doubling PSA time (31.8 months)                                  \[[@r179]\]
  antigen (PSA)                                                                                                                                                                                                                     

  Transcatheter arterial chemoembolization             GTN                  Clinical trial            Liver cancer                 GTN improved the delivery of tumor-targeted therapy *via* enhanced permeability and retention.   \[[@r180]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### A summary of recent examples of NO releasing NPs developed for cancer therapy, with or without combination chemotherapy.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Functional Group**    **Particle**             **Study-Cancer Type**                          **Combined**\            **Stimulus for NO Release**   **References**
                                                                                                  **Anticancer Agent**                                   
  ----------------------- ------------------------ ---------------------------------------------- ------------------------ ----------------------------- ----------------
  NONOate                 Modified silica NP       *In vitro*- ovarian cancer                     None                     None                          \[[@r181]\]

  NONOate                 Modified silica NP       *In vitro -* non-small cell lung cancer        Cisplatin                None                          \[[@r182]\]

  S-nitrosothiol          Micelle                  *In vitro* and *in vivo -* breast cancer       Doxorubicin loaded NPs   None                          \[[@r144]\]

  S-nitrosothiol          Polymeric NP             *In vitro*- ovarian cancer                     Doxorubicin              Vis light                     \[[@r169]\]

  Roussin\'s Black Salt   Metal silica coated NP   *In vitro* - breast cancer                     Doxorubicin              NIR-ray                       \[[@r170]\]

  Nitrobenzene            Polymeric NP             *In vitro* -- cervical\                        None                     UV-ray                        \[[@r127]\]
                                                   cancer                                                                                                

  S-nitrosothiol          Silica NP                *In vitro* - cervical cancer                   Radiotherapy             X-ray                         \[[@r171]\]

  L-arginine              Silica NP                *In vitro* and *in vivo -* pancreatic cancer   None                     Ultrasound                    \[[@r172]\]

  N-nitrosamine           Nano-sandwich            *In vitro* and *in vivo -* breast cancer       Doxorubicin              UV-ray                        \[[@r183]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
